Published in Hepatitis Weekly, July 31st, 2006
"An ex vivo liver slice-culture method was used to develop a novel assay of pretherapy interferon-based suppression," wrote C.T. Yeh and colleagues, Chang Gung Medical Center.
They explained, "To evaluate its clinical application, 45 consecutive patients with chronic hepatitis C were included. They underwent the ex vivo antiviral assay, followed by a 24-week course of therapy with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.